Posted by Michael Wonder on 29 May 2025
ICER publishes evidence report on treatment for secondary progressive multiple sclerosis
29 May 2025 - There are significant uncertainties regarding long term efficacy of tolebrutinib; ICER estimates that treatment would achieve common thresholds of cost effectiveness if priced between $3,250 and $5,900/year.
The ICER today posted its revised evidence report assessing the comparative clinical effectiveness and value of tolebrutinib (Sanofi) for the treatment of secondary progressive multiple sclerosis.
